Applied Genetic Technologies Corp (AGTC)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Susan B. Washer
Employees:
100
14193 NW 119TH TERRACE, SUITE #10, ALACHUA, FL 32615
386-462-2204

Applied Genetic Technologies Corporation develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa. It is also developing an optogenetic product candidate to treat advanced retinal disease.

Data derived from most recent annual or quarterly report
Market Cap 16.91 Million Shares Outstanding42.92 Million Avg 30-day Volume 1.113 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.28
Price to Revenue54.2456 Debt to Equity1.0696 EBITDA-64.889 Million
Price to Book Value0.9991 Operating Margin-20644.307699999998 Enterprise Value-5.469 Million
Current Ratio1.4 EPS Growth0.102 Quick Ratio1.287
1 Yr BETA 0.9941 52-week High/Low 2.83 / 0.23 Profit Margin-21610.4615
Operating Cash Flow Growth-21.5106 Free Cash Flow to Firm (FCFF) TTM -50.395 Million Free Cash Flow to Equity (FCFE) TTM-43.868 Million
Altman Z-Score-11.3427
View SEC Filings from AGTC instead.

View recent insider trading info

Applied Genetic Technologies Corp YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding AGTC (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AGTC

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2022-12-01 by ROBINSON JAMES A. JR.
  • 4: filed on 2022-12-01 by VANLENT ANNE
  • 4: filed on 2022-12-01 by ROSEN JAMES
  • 4: filed on 2022-12-01 by ALISKI WILLIAM
  • 4: filed on 2022-12-01 by HURWITZ EDWARD
  • 4: filed on 2022-12-01 by HASHAD YEHIA
  • 4: filed on 2022-12-01 by KOENIG SCOTT
  • 4: filed on 2022-12-01 by REYNOLDS GERALD ANTHONY
  • 4: filed on 2022-12-01 by SCARIA ABRAHAM
  • 4: filed on 2022-12-01 by POTTER STEPHEN W

    • Events (8k)

  • 8-K: filed on 2022-12-01:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-29:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-23:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-24:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-26:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-08-12:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-07-14:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-16:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-09:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-23:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    HURWITZ EDWARD

    • Director
    		 0 2022-11-30 1

    VANLENT ANNE

    • Director
    		 0 2022-11-30 1

    LIEBER JONATHAN I CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2022-11-30 1

    POTTER STEPHEN W CHIEF BUSINESS OFFICER

    • Officer
    		 0 2022-11-30 1

    KOENIG SCOTT

    • Director
    		 0 2022-11-30 1

    ALISKI WILLIAM

    • Director
    		 0 2022-11-30 1

    WASHER SUSAN B. PRESIDENT AND CEO

    • Officer
    • Director
    		 0 2022-11-30 1

    ROSEN JAMES

    • Director
    		 0 2022-11-30 1

    ROBINSON JAMES A. JR.

    • Director
    		 0 2022-11-30 1

    REYNOLDS GERALD ANTHONY CHIEF ACCOUNTING OFFICER

    • Officer
    		 0 2022-11-30 1

    HASHAD YEHIA

    • Director
    		 0 2022-11-30 1

    SCHNEIDER SUSAN CHIEF MEDICAL OFFICER

    • Officer
    		 0 2022-11-30 1

    SCARIA ABRAHAM CHIEF SCIENTIFIC OFFICER

    • Officer
    		 0 2022-11-30 1

    DOYLEY-GAY HOPE GENERAL COUNSEL

    • Officer
    		 0 2022-11-30 1

    MAGOVCEVIC-LIEBISCH IVANA

    • Director
    		 14,000 2021-11-30 0

    SHEARMAN MARK S CHIEF SCIENTIFIC OFFICER

    • Officer
    		 33,277 2020-08-15 0

    SULLIVAN WILLIAM A. CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2020-08-05 0

    KROL PATRICK JOHAN HENDRIK

    STICHTING AESCAP 2.0

    PRIVIUM FUND MANAGEMENT B.V.

    INSPIRATIONAL VISIONS B.V.

    • 10% Owner
    		 No longer subject to file 2019-12-26 0

    KREX BRIAN GENERAL COUNSEL

    • Officer
    		 0 2019-08-15 0

    FEINSOD MATTHEW EXEC. VP, GLOBAL STRAT. & DEV.

    • Officer
    		 No longer subject to file 2019-07-29 0

    HEAH THERESA CHIEF MEDICAL OFFICER

    • Officer
    		 0 2019-07-29 0

    FEINSOD MATTHEW INTERIM CHIEF MEDICAL OFFICER

    FEINSOD MATTHEW INTERIM CHIEF MEDICAL OFFICER

    • Officer
    		 46,791 2018-12-11 0

    KOENIG SCOTT

    KOENIG SCOTT

    • Director
    		 0 2018-07-25 1

    BULLOCK LAWRENCE E CHIEF FINANCIAL OFFICER

    • Officer
    		 No longer subject to file 2017-08-03 0

    ASHE ANDREW D. GENERAL COUNSEL

    • Officer
    		 0 2017-08-01 0

    GOLDSTEIN MICHAEL H. CHIEF MEDICAL OFFICER

    • Officer
    		 0 2017-07-17 0

    ORONSKY ARNOLD L

    • Director
    		 1,455,904 2017-04-24 0

    CHULAY JEFFREY D. VP AND CHIEF MEDICAL OFFICER

    • Officer
    		 20,400 2016-11-01 0

    PEACOCK BRUCE

    • Director
    		 0 2015-11-19 0

    GLAXOSMITHKLINE PLC

    • FORMER 10% OWNER
    		 No longer subject to file 2015-02-23 0

    MENICHELLA DANIEL L V.P. & CHIEF BUSINESS OFFICER

    • Officer
    		 0 2015-01-23 0

    ALTA PARTNERS VIII, L.P.

    CHAMPSI FARAH

    JANNEY DANIEL

    NOHRA GUY P

    ALTA PARTNERS MANAGEMENT VIII, LLC

    • 10% Owner
    		 No longer subject to file 2014-11-17 0

    KNOP DAVID R. DIRECTOR, PROCESS DEVELOPMENT

    • Officer
    		 0 2014-07-31 0

    GUYER DAVID R

    • Director
    		 0 2014-06-27 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    APPLIED GENETIC TECHNOLOGIES AGTC 2022-11-28 22:15:03 UTC 2.0759 1.7441 350000
    APPLIED GENETIC TECHNOLOGIES AGTC 2022-11-28 21:45:04 UTC 1.9178 1.9022 350000
    APPLIED GENETIC TECHNOLOGIES AGTC 2022-11-28 21:15:03 UTC 1.9178 1.9022 350000
    APPLIED GENETIC TECHNOLOGIES AGTC 2022-11-28 20:45:03 UTC 1.9178 1.9022 250000
    APPLIED GENETIC TECHNOLOGIES AGTC 2022-11-28 20:15:04 UTC 1.9178 1.9022 250000
    APPLIED GENETIC TECHNOLOGIES AGTC 2022-11-28 19:45:03 UTC 1.9178 1.9022 1700000
    APPLIED GENETIC TECHNOLOGIES AGTC 2022-11-28 19:15:03 UTC 1.9178 1.9022 1700000
    APPLIED GENETIC TECHNOLOGIES AGTC 2022-11-28 18:45:05 UTC 2.0206 1.7994 1700000
    APPLIED GENETIC TECHNOLOGIES AGTC 2022-11-28 18:15:04 UTC 2.0206 1.7994 1700000
    APPLIED GENETIC TECHNOLOGIES AGTC 2022-11-28 17:45:04 UTC 2.0206 1.7994 1700000
    APPLIED GENETIC TECHNOLOGIES AGTC 2022-11-28 17:15:04 UTC 2.0206 1.7994 1800000
    APPLIED GENETIC TECHNOLOGIES AGTC 2022-11-28 16:45:03 UTC 2.0555 1.7645 1800000
    APPLIED GENETIC TECHNOLOGIES AGTC 2022-11-28 16:15:03 UTC 2.0555 1.7645 1800000
    APPLIED GENETIC TECHNOLOGIES AGTC 2022-11-28 15:45:04 UTC 2.0555 1.7645 1400000
    APPLIED GENETIC TECHNOLOGIES AGTC 2022-11-28 15:15:03 UTC 2.0555 1.7645 1400000
    APPLIED GENETIC TECHNOLOGIES AGTC 2022-11-28 14:45:03 UTC 2.0555 1.7645 1400000
    APPLIED GENETIC TECHNOLOGIES AGTC 2022-11-28 14:15:03 UTC 2.0555 1.7645 1400000
    APPLIED GENETIC TECHNOLOGIES AGTC 2022-11-28 13:45:04 UTC 1.8261 1.9939 1400000
    APPLIED GENETIC TECHNOLOGIES AGTC 2022-11-28 13:15:03 UTC 1.8261 1.9939 1400000
    APPLIED GENETIC TECHNOLOGIES AGTC 2022-11-28 12:45:03 UTC 1.8261 1.9939 1400000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments